Molecular events in neuroendocrine prostate cancer development

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the mechanisms behind this transdifferentiation are a su...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Urology Jg. 18; H. 10; S. 581 - 596
Hauptverfasser: Wang, Yong, Wang, Yu, Ci, Xinpei, Choi, Stephen Y C, Crea, Francesco, Lin, Dong, Wang, Yuzhuo
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Nature Publishing Group 01.10.2021
Schlagworte:
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Androgen Antagonists - therapeutic use
Androgens
Antineoplastic Agents - therapeutic use
Cell Transdifferentiation
Disease Progression
Humans
Male
Neuroendocrine Tumors - genetics
Neuroendocrine Tumors - metabolism
Neuroendocrine Tumors - pathology
Platinum Compounds - therapeutic use
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - genetics
Prostatic Neoplasms, Castration-Resistant - metabolism
Prostatic Neoplasms, Castration-Resistant - pathology
Receptors, Androgen - metabolism
ISSN:1759-4812, 1759-4820, 1759-4820
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the mechanisms behind this transdifferentiation are a subject of debate. The survival of patients with NEPC is poor, and few effective treatment options are available. To improve clinical outcomes, understanding of the biology and molecular mechanisms regulating NEPC development is crucial. Various NEPC molecular drivers make temporal contributions during NEPC development, and despite the limited treatment options available, several novel targeted therapeutics are currently under research.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1759-4812
1759-4820
1759-4820
DOI:10.1038/s41585-021-00490-0